Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 3rd quarter License agreements included in report

3rd quarter License agreements included in report

posted on Apr 11, 2008 10:08AM

I just spoke with Hawk Associates and confermed that the satatement made in the letter to shareholders," Information contained in our April9,2008 earnings release, which fully reflects the financial results of all transactions announced prior to the end of January 2008", is a corrected statement, the date is not a missprint. Seven transactions to date were announced after the end of January 2008 and should be reported in the Q4 results.

IMO the Financial windfall that PTSC will receive in the J3 patent litigation, " Business Settlement ", is far greater than what is reflected in Q3. Stockholders will appreciate the impact of this settlement as future Quarters are reported.

Share
New Message
Please login to post a reply